Pharmacogenomics and Post-Operative Nausea and Vomiting

Completed · Phase 4

Conditions studied: Postoperative Nausea

In brief

The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.

Key facts

Study ID
NCT03503292
Run by
Mayo Clinic
People needed
92
Starts
2018-05-02
Expected to finish
2019-12-30
Last updated by the study team
2020-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.